Milestones in ataxia
暂无分享,去创建一个
[1] C. Shaw,et al. Lithium Therapy Improves Neurological Function and Hippocampal Dendritic Arborization in a Spinocerebellar Ataxia Type 1 Mouse Model , 2007, PLoS Medicine.
[2] S. Kustermann,et al. Hereditary ataxias and paraplegias in Valle ďAosta, Italy: a study of prevalence and disability , 1995, Acta neurologica Scandinavica.
[3] N. Quinn,et al. Multiple system atrophy--the nature of the beast. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[4] Osamu Onodera,et al. Sporadic ataxias in Japan – a population-based epidemiological study , 2008, The Cerebellum.
[5] L. Baliko,et al. Spinocerebellar Ataxia Types 1, 2, 3 and 6: the Clinical Spectrum of Ataxia and Morphometric Brainstem and Cerebellar Findings , 2008, The Cerebellum.
[6] H. Paulson,et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia , 2004, Nature Medicine.
[7] A. Stray-Pedersen,et al. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. , 2009, Brain : a journal of neurology.
[8] A Dürr,et al. Clinical and genetic abnormalities in patients with Friedreich's ataxia. , 1996, The New England journal of medicine.
[9] M. Lovett,et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. , 1995, Science.
[10] Huda Y. Zoghbi,et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1 , 1993, Nature Genetics.
[11] R. Rosenberg. Joseph disease: an autosomal dominant motor system degeneration. , 1984, Advances in neurology.
[12] Huda Y. Zoghbi,et al. Diseases of Unstable Repeat Expansion: Mechanisms and Common Principles , 2005, Nature Reviews Genetics.
[13] Stéphane Schmucker,et al. Understanding the molecular mechanisms of Friedreich's ataxia to develop therapeutic approaches. , 2010, Human molecular genetics.
[14] Thomas Klockgether,et al. Sporadic ataxia with adult onset: classification and diagnostic criteria , 2010, The Lancet Neurology.
[15] H. Paulson,et al. Physiologic alterations in ataxia: channeling changes into novel therapies. , 2009, Archives of neurology.
[16] Masafumi Ogawa,et al. Pharmacological treatments of cerebellar ataxia , 2008, The Cerebellum.
[17] D. Lynch,et al. Health-related quality of life in children with Friedreich ataxia. , 2010, Pediatric neurology.
[18] J. Dichgans,et al. The aetiology of sporadic adult-onset ataxia. , 2002, Brain : a journal of neurology.
[19] P. Patel,et al. Friedreich's Ataxia: Autosomal Recessive Disease Caused by an Intronic GAA Triplet Repeat Expansion , 1996, Science.
[20] S. Pulst,et al. Deranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 2 , 2009, The Journal of Neuroscience.
[21] J. Greenfield,et al. The Spino‐Cerebellar Degenerations , 1955, Neurology.
[22] Í. Lopes-Cendes,et al. Correlation between CAG repeat length and clinical features in Machado-Joseph disease. , 1995, American journal of human genetics.
[23] Peter L. Lantos,et al. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome) , 1989, Journal of the Neurological Sciences.
[24] X. Chen,et al. Deranged Calcium Signaling and Neurodegeneration in Spinocerebellar Ataxia Type 3 , 2008, The Journal of Neuroscience.
[25] Brent L Fogel,et al. Clinical features and molecular genetics of autosomal recessive cerebellar ataxias , 2007, The Lancet Neurology.
[26] L. Schöls,et al. Autosomal dominant cerebellar ataxia: Phenotypic differences in genetically defined subtypes? , 1997, Annals of neurology.
[27] J Q Trojanowski,et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α‐synuclein , 1998, Annals of neurology.
[28] P. Hagerman,et al. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1 , 2007, The Lancet Neurology.
[29] M. Pandolfo,et al. Development of histone deacetylase inhibitors as therapeutics for neurological disease. , 2009, Future neurology.
[30] P. Serrano-Aguilar,et al. Effectiveness and safety of treatments for degenerative ataxias: A systematic review , 2009, Movement disorders : official journal of the Movement Disorder Society.
[31] D. Rubinsztein,et al. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3 , 2009, Brain : a journal of neurology.
[32] D Ravine,et al. Population based study of late onset cerebellar ataxia in south east Wales , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[33] Thorsten Schmidt,et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis , 2004, The Lancet Neurology.
[34] O. Combarros,et al. Hereditary ataxias and paraplegias in Cantabria, Spain. An epidemiological and clinical study. , 1991, Brain : a journal of neurology.
[35] Lippincott Williams Wilkins,et al. Scale for the assessment and rating of ataxia: Development of a new clinical scale , 2006, Neurology.
[36] Alexandra Durr,et al. Spinocerebellar ataxia 3 and machado‐joseph disease: Clinical, molecular, and neuropathological features , 1996, Annals of neurology.
[37] R. Rosenberg. Machado‐Joseph disease: An autosomal dominant motor system degeneration , 1992, Movement disorders : official journal of the Movement Disorder Society.
[38] Pask Ea,et al. HOMOSEXUALITY AS A CRIME. , 1965 .
[39] A. Harding. CLASSIFICATION OF THE HEREDITARY ATAXIAS AND PARAPLEGIAS , 1983, The Lancet.
[40] Alexandra Durr,et al. Autosomal dominant cerebellar ataxias: polyglutamine expansions and beyond , 2010, The Lancet Neurology.
[41] R. Sinke,et al. Spinocerebellar ataxias in the Netherlands: Prevalence and age at onset variance analysis , 2002, Neurology.
[42] H. Paulson,et al. Polyglutamine neurodegeneration: protein misfolding revisited , 2008, Trends in Neurosciences.
[43] N. Drouot,et al. Ataxia with oculomotor apraxia type 2: clinical, biological and genotype/phenotype correlation study of a cohort of 90 patients. , 2009, Brain : a journal of neurology.
[44] N. Drouot,et al. Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management , 2010, neurogenetics.
[45] X. Estivill,et al. Clinical, neuropathologic, and genetic studies of a large spinocerebellar ataxia type 1 (SCA1) kindred , 1995, Neurology.
[46] S. Perlman,et al. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. , 2010, Archives of neurology.
[47] G. Holmes. AN ATTEMPT TO CLASSIFY CEREBELLAR DISEASE, WITH A NOTE ON MARIE'S HEREDITARY CEREBELLAR ATAXIA , 1908 .
[48] Peter K. Todd,et al. RNA‐mediated neurodegeneration in repeat expansion disorders , 2009, Annals of neurology.
[49] Janghoo Lim,et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1 , 2008, Nature.
[50] S. Katyal,et al. DNA strand breaks, neurodegeneration and aging in the brain , 2008, Mechanisms of Ageing and Development.